These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 19609217)

  • 21. Presentation, treatment, and outcome of type 1 gastric carcinoid tumors.
    Dakin GF; Warner RR; Pomp A; Salky B; Inabnet WB
    J Surg Oncol; 2006 Apr; 93(5):368-72. PubMed ID: 16550587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs.
    Campana D; Nori F; Pezzilli R; Piscitelli L; Santini D; Brocchi E; Corinaldesi R; Tomassetti P
    Endocr Relat Cancer; 2008 Mar; 15(1):337-42. PubMed ID: 18310299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic options for gastrointestinal carcinoids.
    Modlin IM; Latich I; Kidd M; Zikusoka M; Eick G
    Clin Gastroenterol Hepatol; 2006 May; 4(5):526-47. PubMed ID: 16630755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy.
    Christante D; Pommier S; Givi B; Pommier R
    Surgery; 2008 Dec; 144(6):885-93; discussion 893-4. PubMed ID: 19040993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors.
    Buscombe JR; Caplin ME; Hilson AJ
    J Nucl Med; 2003 Jan; 44(1):1-6. PubMed ID: 12515868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies.
    Anthony LB; Woltering EA; Espenan GD; Cronin MD; Maloney TJ; McCarthy KE
    Semin Nucl Med; 2002 Apr; 32(2):123-32. PubMed ID: 11965607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Octreotide in the treatment of advanced pancreatic tumor. Preliminary study].
    Cirillo F; Bottini A; Brunelli A; Zuffada S; Bassi M; Filippini L; Alquati P
    Minerva Chir; 1998 Dec; 53(12):979-85. PubMed ID: 10210927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A single-centre experience with octreotide in the treatment of different hypersecretory syndromes in patients with functional gastroenteropancreatic neuroendocrine tumors.
    Berković MC; Altabas V; Herman D; Hrabar D; Goldoni V; Vizner B; Zjacić-Rotkvić V
    Coll Antropol; 2007 Jun; 31(2):531-4. PubMed ID: 17847934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carcinoid metastasis to the brain.
    Hlatky R; Suki D; Sawaya R
    Cancer; 2004 Dec; 101(11):2605-13. PubMed ID: 15495181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-Term Survival with Long-Acting Somatostatin Analogues Plus Aggressive Cytoreductive Surgery in Patients with Metastatic Neuroendocrine Carcinoma.
    Deutsch GB; Lee JH; Bilchik AJ
    J Am Coll Surg; 2015 Jul; 221(1):26-36. PubMed ID: 26027502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period.
    Anthony L; Vinik AI
    Pancreas; 2011 Oct; 40(7):987-94. PubMed ID: 21697761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Two cases of thymic carcinoid treated with octreotide long-acting repeatable].
    Okabe N; Inoue T; Watanabe Y; Muto S; Hasegawa T; Ohsugi J; Higuchi M; Shio Y; Suzuki H
    Gan To Kagaku Ryoho; 2014 Jul; 41(7):879-83. PubMed ID: 25131876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The evolving landscape of neuroendocrine tumors.
    Bergsland EK
    Semin Oncol; 2013 Feb; 40(1):4-22. PubMed ID: 23391109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Follow-up of patients with ECL cell-derived tumours.
    Sagatun L; Fossmark R; Jianu CS; Qvigstad G; Nordrum IS; Mjønes P; Waldum HL
    Scand J Gastroenterol; 2016 Nov; 51(11):1398-405. PubMed ID: 27309188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ten-year adjuvant treatment with somatostatin analogs in a patient with atypical carcinoid of the lung.
    Buonerba C; Gallo C; Di Lorenzo G; Romeo V; Marinelli A
    Anticancer Drugs; 2010 Apr; 21(4):465-8. PubMed ID: 20075713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of octreotide in the regression of a metastatic carcinoid tumour despite negative imaging with In-111-pentetreotide (Octreoscan).
    Hillman N; Herranz L; Alvarez C; Martínez Olmos MA; Márco A; Gómez-Pan A
    Exp Clin Endocrinol Diabetes; 1998; 106(3):226-30. PubMed ID: 9710364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study.
    Dasari A; Bergsland EK; Benson AB; Cai B; Huynh L; Totev T; Shea J; Duh MS; Neary MP; Dagohoy CG; Shih BE; Maurer VE; Chan J; Kulke MH
    Oncologist; 2019 Aug; 24(8):1066-1075. PubMed ID: 30610008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficient symptomatic control of carcinoid tumors with somatostatin in patients with disease progression under alpha-interferon therapy.
    Boehme MW; Schmidt-Gayk H; Bihl H; Eisenhut M; Herfarth CH; Kommere B; Raeth U
    Hepatogastroenterology; 1995; 42(6):1053-61. PubMed ID: 8847018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids.
    Sullivan I; Le Teuff G; Guigay J; Caramella C; Berdelou A; Leboulleux S; Déandréis D; Hadoux J; Ducreux M; Duvillard P; Adam J; Scoazec JY; Baudin E; Planchard D
    Eur J Cancer; 2017 Apr; 75():259-267. PubMed ID: 28242503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.